Business
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
HOUSTON, Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020. \n\n \n \n \n \n \n \n\n \n\"We continue to make progress toward advancing our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia, or AML,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"While the COVID-19 pandemic has impacted hospital systems globally, we have augmented our process development for our MT-401 product, continued the buildout of our manufacturing facility and added further clinical sites for our Phase 2 AML trial. With a novel cell therapy product candidate that has demonstrated the ability to induce broad and durable immune responses in earlier clinical studies, Marker remains well-positioned to provide a potential treatment option for patients suffering from this devastating disease.\"\nPROGRAM UPDATES\nMulti-Antigen Targeted (MultiTAA) T Cell Therapies\nPhase 2 AML Trial Update The Company continues to identify and add clinical trial sites in preparation for the Phase 2 AML trial initiation. The study is currently subject to a partial clinical hold on the use of a new reagent in the manufacturing process until the FDA reviews and accepts the final data and certificates of analysis for the new reagent. The alternate supplier has been delayed in providing the reagent but expects to ship the reagent to Marker in Q3. Once Marker receives the reagent and completes the required analyses for FDA, the Company will provide additional clarification around the timing of the AML trial enrollment. \nUSAN Council Approval of \"Zelenoleucel\" for MT-401Marker recently announced that the United States Adopted Names (USAN) Council approved \"zelenoleucel\" as the nonproprietary (generic) name for MT-401, a MultiTAA-specific T cell product candidate for the treatment of patients with AML following allogeneic stem cell transplant in both adjuvant and active disease settings.\nPancreatic Cancer Data Presented During ASCO Updated clinical results from an ongoing investigator-s...